Added to YB: 2025-09-04
Pitch date: 2025-09-02
BIOG-B.ST [neutral]
BioGaia AB (publ)
+21.81%
current return
Author Info
Lind Research provides institutional grade investment research in the Nordics. Sign up for the newsletter.
Company Info
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand.
Market Cap
SEK 12.0B
Pitch Price
SEK 100.81
Price Target
N/A
Dividend
3.38%
EV/EBITDA
24.92
P/E
34.50
EV/Sales
7.29
Sector
Biotechnology
Category
growth
Discovery Report: Watchlist add - Biogaia (OM: BIOGB)
BIOG-B.ST watchlist: Swedish probiotic co riding gut health trend. SEK 1.44B revenue, SEK 423M EBIT past 12mo. Pediatrics 75% rev (mid-single digit growth), Adults +20%. Margins compressed due to shift from distributor to direct sales for long-term scalability. New chairman Mauricio Graber insider buying. Valuation still high, waiting for more pessimism.
Read full article (1 min)